NG11-2 Phase-Ib Study Completes Last Patient Visit

A Phase-1b Dose Escalation Study to Assess the Effect of NG11-2 on Radiation Induced Oral Mucositis (RIOM) in Patients with Head & Neck Cancer

21st August 2024 – VasoDynamics Ltd, the pharmaceutical company developing patient-friendly therapies for the prevention of debilitating side-effects induced by anti-cancer treatments, is pleased to report that the last patient study visit took place on 20th August and that the study is now in the Close-out phase.

It is anticipated that the study database will be locked in September with the Clinical Study Report being available towards the end of 2024.

The study is investigating the safety and preliminary efficacy of NG11-2 mouthwash for reducing and preventing Acute Severe Oral Mucositis induced by radiotherapy, a well-known and debilitating side-effect of radiotherapy on patients undergoing treatment for head & neck cancer. The study consisted of a dose escalation phase followed by a dose expansion phase. A total of 15 patients were enrolled, each receiving NG11-2 mouthwash treatment once prior to each of their fractional radiation over the 6 or 7 weeks of radiotherapy, with or without chemotherapy .

Dr Ningfeng Fiona Li, CEO of VasoDynamics, said:

“We are very pleased to close the study on schedule and are looking forward to reporting on the study outcome with the full safety and preliminary efficacy profile of NG11-2 in Q3/4 this year. The readout of this study will support the strategic and operational decisions on the next stage of clinical development and the roadmap towards a market approval of this exciting treatment. The VasoDynamics team would like to thank all the participating clinical sites for their excellent support to help meet this important milestone within the planned timeline.”
For enquiries, please contact:

Dr Ningfeng Fiona Li, CEO +44 7969132263
fiona.li@vasodynamics.co.uk
Gary Bower, COO +44 7960388412
gary.bower@vasodynamics.co.uk

Notes to Editors:

About VasoDynamics

VasoDynamics is a pharmaceutical development company based in Stevenage-London, UK. It is a clinical stage biopharma company with experienced and culture-diversified executives who have shared vision to improve the standard of cancer care globally. Recognising the mounting cost pressures facing healthcare payers all over the world, the company is developing a number of cost-effective medicines, all of which target the prevention of debilitating and often dose-limiting complications of cancer therapy, such as chemotherapy and radiotherapy induced mucositis, dermatitis, and hair-loss. We take great pride in our culture of scientific and development rigour, and our programmes are based on scientific finding and innovations from world-leading research bodies. The company’s proprietary technology platform utilises the different dynamics of normal and cancerous vasculatures developing a serials of pipeline products for various types of cancer patient cohorts, hence to achieve the most effective and patient friendly protections to prevent severe side-effects during various types of cancer treatments.